ArticleCureus2025
Buzzing Away Pain: Efficacy of Buzzy® in Reducing Pain During Canakinumab Treatment for Familial Mediterranean Fever.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Turkish Pain Catastrophizing Scale-Child in Adolescents with Familial Mediterranean Fever: A Psychometric Analysis.Archives of rheumatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn colchicine-resistant patients with familial Mediterranean fever (FMF), alternative therapies, which are administered parenterally, become necessary. Effective pain management is essential for FMF treatment. Buzzy® (Pain Care Labs, Atlanta, GA) is specifically designed to alleviate pain during needle procedures. This innovative tool integrates a cold pack with a vibration motor, thereby enabling the simultaneous application of cold therapy, tactile stimulation, and distraction techniques. By harnessing the combined effects of cold and vibration on the skin, Buzzy® significantly reduces pain perception. This study aimed to evaluate the effectiveness of Buzzy® in mitigating pain during subcutaneous administration of canakinumab in patients with FMF who are resistant to colchicine. This study included patients with colchicine resistance who were receiving canakinumab. Pain scores were evaluated before and after applying Buzzy® using the Visual Analog Scale (VAS), Wong-Baker FACES Pain Rating Scale (FPS-R), and Children's Fear Scale (CFS).
resultsA total of 15 patients were included in the study. Nine patients (60%) were female, and six (40%) were male. The median age of the patients was nine years (five to 18 years). The median VAS, FPS-R, and CFS scores before Buzzy® were four (0 to eight), four (0 to eight), and one (0 to four), respectively. After Buzzy® application, the median VAS, FPS-R, and CFS scores were two (0 to six), two (0 to six), and 0 (0 to three), respectively. The VAS and FPS-R scores showed a significant reduction (p=0.04 and p=0.008, respectively), indicating a notable decrease in pain. Although the CFS scores also decreased following the use of Buzzy®, this reduction was not statistically significant (p=0.526).
conclusionAccording to the gate control theory of pain, methods like Buzzy® temporarily block pain signals from reaching the central nervous system by "closing the gates." In patients requiring continuous injections, such applications may reduce the pain and anxiety they experience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.